EP3733179A4 - Pharmazeutische zubereitung mit einer pyridylaminoessigsäureverbindung - Google Patents

Pharmazeutische zubereitung mit einer pyridylaminoessigsäureverbindung Download PDF

Info

Publication number
EP3733179A4
EP3733179A4 EP18896002.5A EP18896002A EP3733179A4 EP 3733179 A4 EP3733179 A4 EP 3733179A4 EP 18896002 A EP18896002 A EP 18896002A EP 3733179 A4 EP3733179 A4 EP 3733179A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical preparation
pyridylaminoacetic acid
pyridylaminoacetic
acid
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18896002.5A
Other languages
English (en)
French (fr)
Other versions
EP3733179A1 (de
Inventor
Hisashi KAWATA
Noriko Kawabata
Naveed Shams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of EP3733179A1 publication Critical patent/EP3733179A1/de
Publication of EP3733179A4 publication Critical patent/EP3733179A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18896002.5A 2017-12-28 2018-12-27 Pharmazeutische zubereitung mit einer pyridylaminoessigsäureverbindung Withdrawn EP3733179A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611017P 2017-12-28 2017-12-28
PCT/JP2018/048228 WO2019131901A1 (ja) 2017-12-28 2018-12-27 ピリジルアミノ酢酸化合物を含有する医薬製剤

Publications (2)

Publication Number Publication Date
EP3733179A1 EP3733179A1 (de) 2020-11-04
EP3733179A4 true EP3733179A4 (de) 2021-09-15

Family

ID=67067440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18896002.5A Withdrawn EP3733179A4 (de) 2017-12-28 2018-12-27 Pharmazeutische zubereitung mit einer pyridylaminoessigsäureverbindung

Country Status (8)

Country Link
US (2) US11666563B2 (de)
EP (1) EP3733179A4 (de)
JP (1) JP7346305B2 (de)
KR (1) KR102901189B1 (de)
CN (1) CN111526876A (de)
CA (1) CA3087019A1 (de)
TW (1) TWI842692B (de)
WO (1) WO2019131901A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111526876A (zh) 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
WO2021145355A1 (ja) * 2020-01-15 2021-07-22 参天製薬株式会社 近視の治療、近視の予防および／または近視の進行抑制のための医薬組成物
WO2022034909A1 (ja) * 2020-08-13 2022-02-17 参天製薬株式会社 セペタプロストを含有する医薬製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
US20140018396A1 (en) * 2012-07-13 2014-01-16 Santen Pharmaceutical Co., Ltd Combination of sulfonamide compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE042839T2 (hu) 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
HRP20160104T1 (hr) * 2009-03-30 2016-03-25 Ube Industries Farmaceutski pripravak za liječenje ili prevenciju glaukoma
KR101113280B1 (ko) 2009-11-17 2012-03-14 천공전기(주) 인장 클램프
EP2702087B1 (de) 2011-04-28 2015-03-18 Basf Se Halbleitermaterialien auf der basis von thienothiophen-2,5-dion-oligomeren und polymeren
WO2012165639A1 (ja) 2011-06-03 2012-12-06 キヤノン株式会社 トナー
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
GEP20186917B (en) * 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pharmaceutical preparation including pyridylamino acetic acid compound
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
ES2953346T3 (es) 2014-01-10 2023-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado
JP2017002941A (ja) 2015-06-05 2017-01-05 日本精工株式会社 ボールねじ
US10029330B2 (en) 2015-06-17 2018-07-24 The Boeing Company Hybrid laser machining of multi-material stack-ups
EP3318280A4 (de) 2015-07-01 2018-08-22 Santen Pharmaceutical Co., Ltd Depotpräparat mit zitronensäureester
EP3320904B1 (de) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Präventiver und/oder therapeutischer wirkstoff mit pyridyl-aminoessigsäure-verbindung zur behandlung einer krankheit mit einem stark erhöhten innenaugendruck
CN111526876A (zh) 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
US20140018396A1 (en) * 2012-07-13 2014-01-16 Santen Pharmaceutical Co., Ltd Combination of sulfonamide compound

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FENGHE LU ET AL: "A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1 July 2018 (2018-07-01), XP055830538, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2689731> [retrieved on 20210805] *
ROPO AULI M ET AL: "IOP lowering effect of omidenepag isopropyl in latanoprost non-/low-responder subjects with primary open-angle glaucoma or ocular hypertension: the FUJI study |", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1 July 2018 (2018-07-01), XP055830537, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2689729> [retrieved on 20210805] *
SCHMIER JORDANA ET AL: "Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs", CLINICAL OPHTHALMOLOGY, vol. 8, 1 January 2014 (2014-01-01), pages 1097 - 1104, XP055830750, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=20378> DOI: 10.2147/OPTH.S63760 *
See also references of WO2019131901A1 *
TANIGUCHI TAKAZUMI ET AL: "Omidenepag isopropyl, a selective EP2 agonist, shows additive intraocular pressure (IOP)-lowering effects when used concomitantly with existing anti-glaucoma drugs in animal models", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 58, no. 8, 31 May 2017 (2017-05-31), pages 2105, XP009528494, ISSN: 0146-0404 *
YOKO IKEDA ET AL: "Latanoprost Nonresponders with Open-Angle Glaucoma in the Japanese Population", JAPANESE JOURNAL OF OPHTHALMOLOGY ; THE OFFICIAL ENGLISH-LANGUAGE JOURNAL OF THE JAPANESE OPHTHALMOLOGICAL SOCIETY, SPRINGER-VERLAG, TO, vol. 50, no. 2, 1 April 2006 (2006-04-01), pages 153 - 157, XP019375914, ISSN: 1613-2246, DOI: 10.1007/S10384-005-0293-X *

Also Published As

Publication number Publication date
EP3733179A1 (de) 2020-11-04
US20230277515A1 (en) 2023-09-07
TWI842692B (zh) 2024-05-21
JP7346305B2 (ja) 2023-09-19
JPWO2019131901A1 (ja) 2020-12-10
TW201929854A (zh) 2019-08-01
US11666563B2 (en) 2023-06-06
KR102901189B1 (ko) 2025-12-16
CA3087019A1 (en) 2019-07-04
RU2020124742A3 (de) 2022-01-28
KR20200103719A (ko) 2020-09-02
RU2020124742A (ru) 2022-01-28
US12290511B2 (en) 2025-05-06
WO2019131901A1 (ja) 2019-07-04
CN111526876A (zh) 2020-08-11
US20200345713A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
IL297676B1 (en) A sustained-release or delayed-release pharmaceutical composition comprising a deuterated compound
NO2025044I1 (no) Inavolisib or a pharmaceutically acceptable salt thereof
EP3549589A4 (de) Pharmazeutische zusammensetzung mit mitochondrien
EP4072520C0 (de) Pharmazeutische zusammensetzungen mit cabotegravir
NO2026006I1 (no) Elinzanetant or a pharmaceutically acceptable salt thereof
EP2948141C0 (de) Pharmazeutische zusammensetzung mit verbesserter bioverfügbarkeit
MA43108A (fr) Anticorps neutralisant le virus syncytial respiratoire humain
EP4233846C0 (de) Pharmazeutische formulierungen
NO2020029I1 (no) Givosiran eller et farmasøytisk akseptabelt salt derav
EP2954483A4 (de) Verwaltung einer medizinischen vorrichtung mithilfe von assoziationen
EP3454899C0 (de) Pharmazeutische zusammensetzung
DK3380149T3 (da) Lægemiddeladministrationsanordning med en hætte
PT3093018T (pt) Preparação farmacêutica incluindo um composto de ácido piridilaminoacético
PL3518892T3 (pl) Preparat farmaceutyczny zawierający związek insuliny
IL257902B (en) Medicament vial assembly
IL284061A (en) Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
IL290447A (en) Pharmaeutical composition comprising ensifentrine
EP3603642A4 (de) Pharmazeutisches präparat
HUE062326T2 (hu) Fokozott stabilitású gyógyászati készítmény
HUE062184T2 (hu) Helyileg alkalmazható készítmény a sebgyógyulás elõsegítésére
DK3065763T3 (da) Anvendelse af il-22-dimer til fremstilling af et medikament til intravenøs indgivelse
EP3107834C0 (de) Kapsel mit einem vorzugsweise rotationssymmetrisch ausgebildetem kapselkörper
LT3064498T (lt) Pirazolpirimidono arba piroltriazono dariniai, jų paruošimo būdas ir jų farmacinis panaudojimas
EP4037659C0 (de) Pharmazeutische zusammensetzung mit enzalutamid
EP3583943A4 (de) Pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031074

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210818

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/06 20060101ALI20210812BHEP

Ipc: A61K 45/06 20060101ALI20210812BHEP

Ipc: A61K 9/00 20060101ALI20210812BHEP

Ipc: A61K 31/5575 20060101ALI20210812BHEP

Ipc: A61K 31/444 20060101AFI20210812BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240702